US stock return on invested capital analysis and economic value added calculations to identify truly exceptional businesses. Our quality metrics help you find companies that generate superior returns on capital employed.
As of April 6, 2026, Replimune Group Inc. (REPL) trades at $8.59 per share, posting a 2.14% gain on the day. This analysis examines recent trading context, key technical levels, and potential near-term scenarios for the clinical-stage biotechnology firm, which focuses on developing oncolytic immunotherapies for cancer treatment. Recent price action for REPL has been range-bound, with traders closely monitoring key support and resistance marks for signs of a potential shift in short-term momentum
Will Replimune Group (REPL) Stock Outperform Peers | Price at $8.59, Up 2.14% - Oversold Bounce
REPL - Stock Analysis
3974 Comments
1347 Likes
1
Violett
Registered User
2 hours ago
That deserves an epic soundtrack. 🎶
👍 21
Reply
2
Shaelea
Insight Reader
5 hours ago
A bit disappointed I didn’t catch this sooner.
👍 194
Reply
3
Richy
Registered User
1 day ago
Are you secretly a superhero? 🦸♂️
👍 160
Reply
4
Colman
Registered User
1 day ago
I didn’t know humans could do this. 🤷♂️
👍 227
Reply
5
Avangelina
Engaged Reader
2 days ago
This activated my inner expert for no reason.
👍 268
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.